IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published on: December 3, 2024
Medical Professional
CYTOPV in the context of PROUD/CONTI and goals of therapy in PV
Dr. Andrew Kuykendall describes the safety and tolerability of avapritinib in AdvSM(Video 3/3)
Andrew Kuykendall, MD
Dr. Katy Beckermann describes the safety of erdafitinib and practical strategies for managing patients with FGFR-mutated mUC (Video 3/3)
Katy Beckermann, MD
Dr. Sara Tolaney discusses the potential impact of 1L sacituzumab govitecan on clinical practice in PDL1+ mTNBC (Video 3/3)
Sara Tolaney, MD
Dr. Hossein Borghaei shows the 6-year results of nivo/ipi + chemo in mNSCLC in patients with squamous histology and high-risk mutations. (Video 2/3)
Hossein Borghaei, MD
Dr. Gregory Vidal discusses safety, tolerability, and NCCN categorization of margetuximab-cmkb in HER2+ mBC (Video 3/3)
Gregory Vidal
Dr. Janjigian discusses the addition of durvalumab to FLOT chemotherapy in gastroesophageal cancer (Video 3/3)
Yelena Janjigian, MD